Comprehensive Nomograms Using Routine Biomarkers Beyond Eosinophil Levels: Enhancing Predictability of Corticosteroid Treatment Outcomes in AECOPD

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2023. Available from: https://goldcopd.org/2023-gold-reports-2/. Accessed April 20, 2023.
   Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:CD001288.
   Google Scholar
• Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi:10.1136/bmj.j1415
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-7
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. doi:10.1164/rccm.201502-0235LE
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3):789–791. doi:10.1183/09031936.00062614
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55. doi:10.1164/rccm.201108-1553OC
   PubMed Web of Science ®Google Scholar
• Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699–709. doi:10.1016/S2213-2600(19)30176-6
   PubMed Web of Science ®Google Scholar
• Li J, Liang L, Feng L, et al. The prognostic value of blood eosinophil level in AECOPD is influenced by corticosteroid treatment during hospitalization. J Inflamm Res. 2023;16:3233–3243. doi:10.2147/JIR.S421605
   PubMed Web of Science ®Google Scholar
• Liu T, Xiang ZJ, Hou XM, Chai JJ, Yang YL, Zhang XT. Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:20406223211028768. doi:10.1177/20406223211028768
   Web of Science ®Google Scholar
• Wang JM, Han MK, Labaki WW. Chronic obstructive pulmonary disease risk assessment tools: is one better than the others? Curr Opin Pulm Med. 2022;28(2):99–108. doi:10.1097/MCP.0000000000000833
   PubMed Web of Science ®Google Scholar
• Nuñez A, Marras V, Harlander M, et al. Clinical and spirometric variables are better predictors of COPD exacerbations than routine blood biomarkers. Respir Med. 2020;171:106091. doi:10.1016/j.rmed.2020.106091
   PubMed Web of Science ®Google Scholar
• Halner A, Beer S, Pullinger R, Bafadhel M, Russell REK, Demidenko E. Predicting treatment outcomes following an exacerbation of airways disease. PLoS One. 2021;16(8):e0254425. doi:10.1371/journal.pone.0254425
   PubMed Web of Science ®Google Scholar
• Yu X, Zhu GP, Cai TF, Zheng JY. Establishment of risk prediction model and risk score for in-hospital mortality in patients with AECOPD. Clin Respir J. 2020;14(11):1090–1098. doi:10.1111/crj.13246
   PubMed Web of Science ®Google Scholar
• Gomez-Rosero JA, Caceres-Galvis C, Ascuntar J, Atencia C, Vallejo CE, Jaimes F. Biomarkers as a Prognostic Factor in COPD Exacerbation: a Cohort Study. COPD. 2021;18(3):325–332. doi:10.1080/15412555.2021.1922370
   PubMedGoogle Scholar
• Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969. doi:10.1183/09031936.00012408
   PubMed Web of Science ®Google Scholar
• Peng JC, Nie F, Li YJ, Xu QY, Xing SP, Gao Y. Prognostic nutritional index as a predictor of 30-day mortality among patients admitted to intensive care unit with acute exacerbation of chronic obstructive pulmonary disease: a single-center retrospective cohort study. Med Sci Monit. 2022;28:e934687. doi:10.12659/MSM.934687
   PubMed Web of Science ®Google Scholar
• Baldemir R, Cirik MO. Practical parameters that can be used for nutritional assessment in patients hospitalized in the intensive care unit with the diagnosis of chronic obstructive pulmonary disease: prognostic nutritional index, neutrophil-to-lymphocyte, platelet-to-lymphocyte, and lymphocyte-to-monocyte ratio. Medicine. 2022;101(24):e29433. doi:10.1097/MD.0000000000029433
   PubMed Web of Science ®Google Scholar
• Peng JC, Gong WW, Wu Y, Yan TY, Jiang XY. Development and validation of a prognostic nomogram among patients with acute exacerbation of chronic obstructive pulmonary disease in intensive care unit. BMC Pulm Med. 2022;22(1):306. doi:10.1186/s12890-022-02100-0
   PubMed Web of Science ®Google Scholar
• Chen L, Chen LJ, Zheng H, Wu SY, Wang SB. Emergency admission parameters for predicting in-hospital mortality in patients with acute exacerbations of chronic obstructive pulmonary disease with hypercapnic respiratory failure. BMC Pulm Med. 2021;21:1.
   PubMed Web of Science ®Google Scholar
• Hu WP, Lhamo T, Liu D, et al. Development of a nomogram to predict the risk of 30-day re-exacerbation for patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. J Chronic Obstruct Pulmon Dis. 2019;16(2):160–167. doi:10.1080/15412555.2019.1606187
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Yamauchi Y, Yasunaga H, et al. Development of a nomogram for predicting in-hospital mortality of patients with exacerbation of chronic obstructive pulmonary disease. Int J Chronic Obstr. 2017;12:1605–1611. doi:10.2147/COPD.S129714
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li J, Liang L. Establishment and application of the data quality control system of an electronic medical record-based big data platform for respiratory diseases. J Med Inform. 2022;7(43):55–60.
   Google Scholar
• Mathioudakis AG, Abroug F, Agusti A, et al. ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. Eur Respir J. 2022;59(5):2102006. doi:10.1183/13993003.02006-2021
   PubMed Web of Science ®Google Scholar
• Suehs CM, Zysman M, Chenivesse C, et al. Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study. BMJ Open. 2020;10(7):e035811. doi:10.1136/bmjopen-2019-035811
   PubMed Web of Science ®Google Scholar
• Liang L, Li C, Shen Y, Rong H, Jing H, Tong Z. Long-term trends in hospitalization and outcomes in adult patients with exacerbation of chronic obstructive pulmonary disease in Beijing, China, from 2008 to 2017. Int J Chron Obstruct Pulmon Dis. 2020;15:1155–1164. doi:10.2147/COPD.S238006
   PubMed Web of Science ®Google Scholar
• Breiman L, Fridman JH, Olshen RA, Stone CJ. Classification and Regression Trees. 1st ed. New York: Routledge; 1984.
   Google Scholar
• Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774–781. doi:10.1016/S0895-4356(01)00341-9
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Vogrin S, Chua KYL, et al. Development and validation of a penicillin allergy clinical decision rule. JAMA Intern Med. 2020;180(5):745–752. doi:10.1001/jamainternmed.2020.0403
   PubMed Web of Science ®Google Scholar
• Gong Y, Sun H. Relationship between blood eosinophils and systemic corticosteroid therapy in COPD exacerbation. Int J Gen Med. 2022;15:7459–7466. doi:10.2147/IJGM.S383940
   PubMed Web of Science ®Google Scholar
• Mao Y, Qian Y, Sun X, Li N, Huang H. Eosinopenia predicting long-term mortality in hospitalized acute exacerbation of COPD patients with community-acquired pneumonia-A Retrospective Analysis. Int J Chron Obstruct Pulmon Dis. 2021;16:3551–3559. doi:10.2147/COPD.S347948
   PubMed Web of Science ®Google Scholar
• Pu J, Yi Q, Luo Y, et al. Blood eosinophils and clinical outcomes in inpatients with acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. Int J Chronic Obstr. 2023;18:169–179. doi:10.2147/COPD.S396311
   PubMed Web of Science ®Google Scholar
• MacDonald MI, Osadnik CR, Bulfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest. 2019;156(1):92–100. doi:10.1016/j.chest.2019.02.406
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Endo-phenotyping of COPD patients. Expert Rev Respir Med. 2021;15(1):27–37. doi:10.1080/17476348.2020.1804364
   PubMed Web of Science ®Google Scholar
• Li L, Zhao N, Ma X, et al. Personalized variable vs fixed-dose systemic corticosteroid therapy in hospitalized patients with acute exacerbations of COPD: a prospective, multicenter, randomized, open-label clinical trial. Chest. 2021;160(5):1660–1669. doi:10.1016/j.chest.2021.05.024
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75(6):520–527. doi:10.1136/thoraxjnl-2019-214484
   PubMed Web of Science ®Google Scholar
• Benson VS, Hartl S, Barnes N, Galwey N, Van Dyke MK, Kwon N. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur Respir J. 2022;59:1. doi:10.1183/13993003.04590-2020
   Web of Science ®Google Scholar
• Colak Y, Afzal S, Nordestgaard BG, Marott JL, Lange P. Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the Copenhagen General Population Study. Eur Respir J. 2018;52(2):2. doi:10.1183/13993003.00616-2018
   Web of Science ®Google Scholar
• Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet. 2004;363(9410):731–733. doi:10.1016/S0140-6736(04)15650-X
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.011
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J. 2017;50:1.
   Web of Science ®Google Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185. doi:10.1183/09031936.00128008
   PubMed Web of Science ®Google Scholar
• Huang D, He DX, Gong LJ, et al. A prediction model for hospital mortality in patients with severe community-acquired pneumonia and chronic obstructive pulmonary disease. Respir Res. 2022;23(1). doi:10.1186/s12931-022-02181-9
   Web of Science ®Google Scholar
• Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J. 2019;53:5. doi:10.1183/13993003.02014-2018
   Web of Science ®Google Scholar
• Wang C, Zhou J, Wang J, et al. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct Target Ther. 2020;5(1):248. doi:10.1038/s41392-020-00345-x
   PubMed Web of Science ®Google Scholar
• Lesourd BM. Nutrition and immunity in the elderly: modification of immune responses with nutritional treatments. Am J Clin Nutr. 1997;66(2):478S–484S. doi:10.1093/ajcn/66.2.478S
   PubMed Web of Science ®Google Scholar
• Reed RM, Iacono A, DeFilippis A, Eberlein M, Girgis RE, Jones S. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J Heart Lung Transplant. 2011;30(6):674–678. doi:10.1016/j.healun.2010.12.010
   PubMed Web of Science ®Google Scholar
• Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005;24(1):16–31. doi:10.1016/j.clnu.2004.08.004
   PubMed Web of Science ®Google Scholar
• Luo Z, Zhang W, Chen L, Xu N. Prognostic value of neutrophil: lymphocyte and platelet: lymphocyte ratios for 28-day mortality of patients with AECOPD. Int J Gen Med. 2021;14:2839–2848. doi:10.2147/IJGM.S312045
   PubMed Web of Science ®Google Scholar
• Yao CY, Liu XL, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chronic Obstr. 2017;12:2285–2290. doi:10.2147/COPD.S141760
   PubMed Web of Science ®Google Scholar
• Eriksson O, Mohlin C, Nilsson B, Ekdahl KN. The human platelet as an innate immune cell: interactions between activated platelets and the complement system. Front Immunol. 2019;10:10. doi:10.3389/fimmu.2019.00010
   PubMed Web of Science ®Google Scholar
• Melki I, Tessandier N, Zufferey A, Boilard E. Platelet microvesicles in health and disease. Platelets. 2017;28(3):214–221. doi:10.1080/09537104.2016.1265924
   PubMed Web of Science ®Google Scholar
• Mallah H, Ball S, Sekhon J, Parmar K, Nugent K. Platelets in chronic obstructive pulmonary disease: an update on pathophysiology and implications for antiplatelet therapy. Respir Med. 2020;3:171.
   Google Scholar
• Lefrancais E, Looney MR. Platelet biogenesis in the lung circulation. Physiology. 2019;34(6):392–401. doi:10.1152/physiol.00017.2019
   PubMed Web of Science ®Google Scholar
• David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. doi:10.1136/thoraxjnl-2020-215167
   PubMed Web of Science ®Google Scholar
• Cabrera López C, Sánchez Santos A, Lemes Castellano A, et al. Eosinophil subtypes in adults with asthma and adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208(2):155–162. doi:10.1164/rccm.202301-0149OC
   PubMed Web of Science ®Google Scholar
• Freeman CM, Curtis JL, Hastie AT. Finding the right biological: eosinophil subset differences in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208(2):121–123. doi:10.1164/rccm.202305-0811ED
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhang W, Ma Y, Zhan Z, Chen Y. Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study. Respir Res. 2021;22(1). doi:10.1186/s12931-021-01888-5
   Web of Science ®Google Scholar
• Zhang Y, Liang L-R, Zhang S, et al. Blood eosinophilia and its stability in hospitalized COPD exacerbations are associated with lower risk of all-cause mortality. Int J Chronic Obstr. 2020;15:1123–1134. doi:10.2147/COPD.S245056
   PubMed Web of Science ®Google Scholar
• Schumann DM, Tamm M, Kostikas K, Stolz D. Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD. Chest. 2019;156(3):456–465. doi:10.1016/j.chest.2019.04.012
   PubMed Web of Science ®Google Scholar